Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition

Breast Cancer Research and Treatment

Volumn 116, Issue 2, 2009, Pages 273-279

  Köster, Frank ^a   Engel, Jörg B ^b   Schally, Andrew V ^c,d   Hönig, Arnd ^b   Schröer, Andreas ^a   Seitz, Stephan ^c,d,e   Hohla, Florian ^c,d   Ortmann, Olaf ^e   Diedrich, Klaus ^a   Buchholz, Stefan ^c,d,e  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Breast cancer; GHRH antagonist; Growth hormone releasing hormone; MAP kinase; Triple negative

Indexed keywords

ANTINEOPLASTIC AGENT; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MZ J 7 118; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; DRUG ACTIVITY; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; RECEPTORS, NEUROPEPTIDE; RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERMORELIN;

EID: 67649225452     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0120-4     Document Type: Article

References (43)

1. Carey LA, Dees EC, Sawyer L et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334. doi:10.1158/1078- 0432.CCR-06-1109
2. Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434. doi:10.1158/1078-0432.CCR-06- 3045
3. Bauer KR, Brown M, Cress RD et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)- negative, and HER2-negative invasive breast cancer, the socalled triple-negative phenotype: a population-based study from the California cancer registry. Cancer 109:1721-1728. doi:10.1002/cncr.22618
4. Morris GJ, Naidu S, Topham AK et al (2007) Differences in breast carcinoma characteristics in newly diagnosed African- American and Caucasian patients: a single-institution compilation compared with the national cancer institute's surveillance, epidemiology, and end results database. Cancer 110:876-884. doi:10.1002/cncr.22836
5. Rakha EA, El-Sayed ME, Green AR et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25-32. doi:10.1002/cncr.22381
6. Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652-5657. doi:10.1200/JCO.2006.06.5664
7. Tischkowitz M, Brunet JS, Begin LR et al (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7:134. doi:10.1186/1471- 2407-7-134
8. Schally AV, Comaru-Schally AM, Nagy A et al (2001) Hypothalamic hormones and cancer. Front Neuroendocrinol 22:248-
9. doi:10.1006/frne.2001.0217
10. Schally AV, Varga JL (1999) Antagonistic analogs of growth hormone-releasing hormone: new potential antitumor agents. Trends Endocrinol Metab 10:383-391. doi:10.1016/S1043- 2760(99)00209-X
11. Varga JL, Schally AV, Csernus VJ et al (1999) Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc Natl Acad Sci USA 96:692-697. doi:10.1073/pnas.96.2.692
12. Varga JL, Schally AV, Horvath JE et al (2004) Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10. Proc Natl Acad Sci USA 101:1708- 1713. doi:10.1073/pnas.0307288101
13. Schally AV, Varga JL, Engel JB (2008) Antagonists of growthhormone- releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 4:33-43. doi:10.1038/ ncpendmet0677
14. Kahan Z, Varga JL, Schally AV et al (2000) Antagonists of growth hormone-releasing hormone arrest the growth of MDAMB- 468 estrogen-independent human breast cancers in nude mice. Breast Cancer Res Treat 60:71-79. doi:10.1023/ A:1006363230990
15. Kiaris H, Schally AV, Varga JL et al (1999) Growth hormonereleasing hormone: an autocrine growth factor for small cell lung carcinoma. Proc Natl Acad Sci USA 96:14894-14898. doi:10.1073/pnas.96.26.14894
16. Chatzistamou I, Schally AV, Varga JL et al (2001) Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormonereleasing hormone. Anticancer Drugs 12:761-768. doi:10.1097/ 00001813-200110000-00008
17. Szepeshazi K, Schally AV, Armatis P et al (2001) Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth. Endocrinology 142:4371-4378. doi:10.1210/en.142.10.4371
18. Csernus VJ, Schally AV, Kiaris H et al (1999) Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proc Natl Acad Sci USA 96:3098-3103. doi:10.1073/ pnas.96.6.3098
19. Rekasi Z, Varga JL, Schally AV et al (2000) Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers. Endocrinology 141:2120-2128. doi:10.1210/ en.141.6.2120
20. Busto R, Schally AV, Braczkowski R et al (2002) Expression of mRNA for growth hormone-releasing hormone and splice variants of GHRH receptors in human malignant bone tumors. Regul Pept 108:47-53. doi:10.1016/S0167-0115(02)00109-X
21. Busto R, Schally AV, Varga JL et al (2002) The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas. Proc Natl Acad Sci USA 99:11866-11871. doi:10.1073/ pnas.182433099
22. Plonowski A, Schally AV, Letsch M et al (2002) Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor. Prostate 52:173-182. doi:10.1002/pros.10105
23. Szepeshazi K, Schally AV, Groot K et al (2000) Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Br J Cancer 82:1724-1731. doi:10.1054/bjoc.2000.1223
24. Szepeshazi K, Schally AV, Groot K et al (2000) Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours. Eur J Cancer 36:128-136. doi:10.1016/ S0959-8049(99)00230-0
25. Chatzistamou I, Schally AV, Varga JL et al (2001) Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide. J Cancer Res Clin Oncol 127:645- 652
26. Chatzistamou I, Schally AV, Varga JL et al (2001) Antagonists of growth hormone-releasing hormone and somatostatin analog RC- 160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice. J Clin Endocrinol Metab 86:2144-2152. doi:10.1210/jc.86.5.2144
27. Frohman LA, Szabo M (1981) Ectopic production of growth hormone-releasing factor by carcinoid and pancreatic islet tumors associated with acromegaly. Prog Clin Biol Res 74:259-271
28. Kahan Z, Arencibia JM, Csernus VJ et al (1999) Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. J Clin Endocrinol Metab 84:582-589. doi:10.1210/jc.84.2.582
29. Plonowski A, Schally AV, Busto R et al (2002) Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers. Peptides 23:1127-1133. doi:10.1016/S0196-9781(02) 00043-8
30. Garcia-Fernandez MO, Schally AV, Varga JL et al (2003) The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation. Breast Cancer Res Treat 77:15-26. doi:10.1023/ A:1021196504944
31. Szereday Z, Schally AV, Varga JL et al (2003) Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma. Cancer Res 63:7913-7919
32. Halmos G, Schally AV, Czompoly T et al (2002) Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer. J Clin Endocrinol Metab 87:4707- 4714. doi:10.1210/jc.2002-020347
33. Benlot C, Levy L, Fontanaud P et al (1997) Somatostatin and growth hormone-releasing hormone in normal and tumoral human breast tissue: endogenous content, in vitro pulsatile release, and regulation. J Clin Endocrinol Metab 82:690-696. doi:10.1210/jc.82.2.690
34. Rekasi Z, Czompoly T, Schally AV et al (2000) Isolation and sequencing of cDNAs for splice variants of growth hormonereleasing hormone receptors from human cancers. Proc Natl Acad Sci USA 97:10561-10566. doi:10.1073/pnas.180313297
35. Halmos G, Schally AV, Varga JL et al (2000) Human renal cell carcinoma expresses distinct binding sites for growth hormonereleasing hormone. Proc Natl Acad Sci USA 97:10555-10560. doi:10.1073/pnas.180313097
36. Chopin LK, Herington AC (2001) A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines. Prostate 49:116-121. doi:10.1002/pros.1125
37. Szereday Z, Schally AV, Nagy A et al (2002) Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215. Br J Cancer 86:1322-1327. doi:10.1038/sj.bjc.6600235
38. Kovacs M, Kineman RD, Schally AV et al (2000) Increase in mRNA concentrations of pituitary receptors for growth hormonereleasing hormone and growth hormone secretagogues after neonatal monosodium glutamate treatment. J Neuroendocrinol 12:335-341. doi:10.1046/j.1365-2826.2000.00458.x
39. Kiaris H, Schally AV, Busto R et al (2002) Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs. Proc Natl Acad Sci USA 99:196-200. doi:10.1073/pnas.012590999
40. Siriwardana G, Bradford A, Coy D et al (2006) Autocrine/paracrine regulation of breast cancer cell proliferation by growth hormone releasing hormone via Ras, Raf, and mitogen-activated protein kinase. Mol Endocrinol 20:2010-2019. doi:10.1210/ me.2005-0001
41. Havt A, Schally AV, Halmos G et al (2005) The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci USA 102:17424-17429. doi:10.1073/pnas.0506844102
42. Chatzistamou I, Schally AV, Kiaris H et al (2004) Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers. Eur J Endocrinol 151:391-396. doi:10.1530/eje.0.1510391
43. Buchholz S, Schally AV, Engel JB et al (2007) Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Proc Natl Acad Sci USA 104:1943-1946. doi:10.1073/pnas.0610860104